s
sumatriptan
Chemical compound
Also known as GR-43175C · Imigran® · 3-(2-(dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide · 3-[2-(dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide · (3-[2-(dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide · 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide
- Formula
- C₁₄H₂₁N₃O₂S
1
- C₁₄H₂₁N₃O₂S
- Mass
- 295.1354 Da
1
- 295.1354 Da
Overview
Chemistry
All data
113 statements · 73% with external sources · numbers in brackets are citations
- Significant drug interaction
- isocarboxazid
- phenelzine
- tranylcypromine
- ergotamine side effect: vasoconstriction
- vortioxetine side effect: geniospasm
- vortioxetine side effect: mental status change
- vortioxetine side effect: hyperthermia
- vortioxetine side effect: hypertension
Show 20 moreShow less
- linezolid side effect: mental status change
- linezolid side effect: geniospasm
- linezolid side effect: hyperthermia
- linezolid side effect: hypertension
- moclobemide side effect: mental status change
- moclobemide side effect: geniospasm
- moclobemide side effect: hyperthermia
- moclobemide side effect: hypertension
- rasagiline side effect: mental status change
- rasagiline side effect: geniospasm
- rasagiline side effect: hyperthermia
- rasagiline side effect: hypertension
- phenelzine side effect: mental status change
- phenelzine side effect: geniospasm
- phenelzine side effect: hyperthermia
- phenelzine side effect: hypertension
- (−)-selegiline side effect: mental status change
- (−)-selegiline side effect: geniospasm
- (−)-selegiline side effect: hyperthermia
- (−)-selegiline side effect: hypertension
- Canonical SMILES
- CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C
1
- CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C
- Medical condition treated
- migraine
1
Sources- 1.Stated in Drug Indications Extracted from FAERSRetrieved 2018-10-02
- migraine with aura(since 1997) approved by: United States Food and Drug Administration
1
Sources- 1.Stated in Inxight: Drugs Databasedrugs.ncats.io/drug/8R78F6L9VORetrieved 2018-11-02
- migraine without aura(since 1997) approved by: United States Food and Drug Administration
1
Sources- 1.Stated in Inxight: Drugs Databasedrugs.ncats.io/drug/8R78F6L9VORetrieved 2018-11-02
- giant cell arteritis(since 1997) approved by: United States Food and Drug Administration
1
Sources- 1.Stated in Inxight: Drugs Databasedrugs.ncats.io/drug/8R78F6L9VORetrieved 2018-11-02
- migraine
- Physically interacts with
- 5-hydroxytryptamine receptor 1A subject has role: agonist
1
- 5-hydroxytryptamine receptor 1B subject has role: agonist
1
- 5-hydroxytryptamine receptor 1D subject has role: agonist
1
- 5-hydroxytryptamine receptor 1E subject has role: agonist
1
- 5-hydroxytryptamine receptor 1F subject has role: agonist
1
- 5-hydroxytryptamine receptor 5A subject has role: agonist
1
- 5-hydroxytryptamine (serotonin) receptor 5A subject has role: agonist
1
- 5-hydroxytryptamine receptor 6 subject has role: agonist
1
Show 1 moreShow less
- 5-hydroxytryptamine receptor 7 subject has role: agonist
1
- 5-hydroxytryptamine receptor 1A subject has role: agonist
- Stylized name
- SUMAtriptan has characteristic: Tall Man lettering · issued by: Institute for Safe Medication Practices
1
Sources- 1.ismp.org/recommendations/tall-man-letters-listRetrieved 2022-09-02
- SUMAtriptan has characteristic: Tall Man lettering · issued by: Institute for Safe Medication Practices
- Defined daily dose
- 50 milligram route of administration: oral administration
- 6 milligram route of administration: parenteral route of administration
- 25 milligram route of administration: rectal route of administration
- Substance control status
- Schedule I (Russia) applies to jurisdiction: Russia
1
Sources- 1.Stated in Government Decree No. 681 of 30 June 1998 (Russia)consultant.ru/document/cons_doc_LAW_19243/Retrieved 2026-08-31
- Schedule I (Russia) applies to jurisdiction: Russia
On other databases
45 identifiers linking sumatriptan across the web's reference databases
- ATC codeN02CC01
- CAS Registry Number103628-46-2
- ChEBI ID10650
- ChEMBL IDCHEMBL128
- ChemSpider ID5165
- DeCS ID31024
- DrugBank IDDB00669
- DrugCentral ID2543
- DSSTOX compound identifierDTXCID303628
- DSSTox substance IDDTXSID4023628
- EC number600-462-9
- ECHA Substance Infocard ID100.130.518
- Electronic Essential Medicines List medicine ID571
- Freebase ID/m/02v5rk
- Guide to Pharmacology Ligand ID54
- History of Modern Biomedicine IDsumatriptan
- HSDB ID7742
- Human Metabolome Database IDHMDB0005037
- InChIInChI=1S/C14H21N3O2S/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3/h4-5,8-9,15-16H,6-7,10H2,1-3H3
- InChIKeyKQKPFRSPSRPDEB-UHFFFAOYSA-N
- J9U entity ID987007534729305171
- KBpedia IDSumatriptan
- KEGG IDC07319
- Library of Congress Authorities IDsh96010267
- MedlinePlus drug identifiera601116
- MeSH concept IDM0027392
- MeSH descriptor IDD018170
- MeSH tree codeD02.065.884.750
- Microsoft Academic ID (discontinued)2778871607
- NDF-RT IDN0000148514
- NE.se IDsumatriptan
- OpenAlex IDC2778871607
- PatientsLikeMe treatment IDsumatriptan
- Probes And Drugs IDPD000904
- PubChem CID5358
- Reaxys registry number5346011
- RxNorm CUI37418
- SPLASHsplash10-0a4i-9400000000-93cc7dc7e521f98aa292
- SureChEMBL ID1482
- UMLS CUIC0075632
- UniChem compound ID389052
- UNII8R78F6L9VO
- UNSPSC code51142414
- WikiProjectMed IDSumatriptan
- Yale LUX IDconcept/bfdb6103-ffa5-4caf-a5fd-57eac8224675